• Telix Pharmaceuticals reported H1 2026 revenue of US$477 million, up 22% year over year.
• Net profit swung to US$38 million; operating profit climbed to US$46 million.
• Adjusted EBITDA (non-IFRS) more than doubled to US$52 million, while cash balance rose 78% to US$252 million.
• R&D spending increased 51% to US$124 million; other income included a US$40 million upfront payment from Regeneron.
• FY 2026 revenue guidance stayed at US$950 million-US$970 million, with revenue expected at the upper end of the range.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein.